These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33752391)

  • 21. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
    J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.
    Ramji A; Doucette K; Cooper C; Minuk GY; Ma M; Wong A; Wong D; Tam E; Conway B; Truong D; Wong P; Barrett L; Ko HH; Haylock-Jacobs S; Patel N; Kaplan GG; Fung S; Coffin CS
    World J Gastroenterol; 2022 Aug; 28(31):4390-4398. PubMed ID: 36159017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
    Liu Y; Cathcart AL; Delaney WE; Kitrinos KM
    J Virol Methods; 2017 Nov; 249():189-193. PubMed ID: 28923315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm.
    Hsu YC; Tseng CH; Kao JH
    Clin Mol Hepatol; 2023 Oct; 29(4):869-890. PubMed ID: 36916171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
    Majeed NA; Alawad AS; Liem KS; Takyar V; Alter H; Feld JJ; Janssen HLA; Ghany MG
    Dig Dis Sci; 2023 Jul; 68(7):3193-3198. PubMed ID: 37022602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
    Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
    World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection technology and clinical applications of serum viral products of hepatitis B virus infection.
    Liu Y; Wu D; Zhang K; Ren R; Liu Y; Zhang S; Zhang X; Cheng J; Chen L; Huang J
    Front Cell Infect Microbiol; 2024; 14():1402001. PubMed ID: 39035352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus.
    Kiruthika S; Bhat R; Dash R; Rathore AS; Vivekanandan P; Jayaram B
    Sci Rep; 2021 Jun; 11(1):11723. PubMed ID: 34083665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
    Seto WK; Liu KS; Mak LY; Cloherty G; Wong DK; Gersch J; Lam YF; Cheung KS; Chow N; Ko KL; To WP; Fung J; Yuen MF
    Gut; 2021 Apr; 70(4):775-783. PubMed ID: 32759300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
    Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B.
    Jeng WJ; Papatheodoridis GV; Lok ASF
    Lancet; 2023 Mar; 401(10381):1039-1052. PubMed ID: 36774930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.